FDA approved a premarket approval supplement application for Novocure’s second generation Optune system. The Tumor Treating Fields delivery system is now available to glioblastoma patients in the U.S. The new model features a generator that is less than half the weight and half the size of the generator in the first generation system. Additional improvements...
New research led by Friends of Cancer Research demonstrates that decreases in circulating tumor DNA after initiation of treatment are associated with improved overall survival in patients with advanced non-small cell lung cancer treated with immunotherapy or chemotherapy.
